NXGL
NEXGEL, INC.
$0.5510
-6.61%
$5.1M
No data for this timeframe.
Vol
Market Cap$5.1M
Cap SizeNano Cap
Inst. Holders7 funds
Inst. Value$130.5K
Inst. Activity0 buys / 1 sells
Insider Activity6B / 6S
Insider Net $$1.1M
Reddit Sentiment60° Warm
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001468929·Prev Close $0.5900
Recent Activity
Jun 8, 2026
Insider
Levy Adam R. sold 3,000 shares
Chief Executive Officer @ $0.5470 ($1.6K)
Jun 4, 2026
Insider
Levy Adam R. sold 3,000 shares
Chief Executive Officer @ $0.5936 ($1.8K)
Jun 1, 2026
Insider
Levy Adam R. sold 2,000 shares
Chief Executive Officer @ $0.5859 ($1.2K)
May 19, 2026
SEC
Three NEXGEL insiders, including CEO Adam Levy and two directors, made open-market purchases totaling $1.09M at $0.60/sh
CLUSTER — Impact 8/10
May 18, 2026
earnings_calendar
NXGL Q1 2026 Earnings Scheduled — 2026-05-18
May 12, 2026
SEC
NEXGEL reported Q4 2025 EPS of -$0.12, a 71.4% miss vs the $0.07 consensus estimate, with revenue of $3.9M in line. The
PRESS-RELEASE — Impact 7/10
Inst.
MORGAN STANLEY — TRIM
54,980 shares ($34.8K)
Inst.
VANGUARD GROUP INC — ADD
123,609 shares ($301.6K)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$2.00 (Mar 2026)
Current $0.5510
Low $2.00
Median $2.00
High $2.00
1 analysts
$2.00
$2.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Maxim Group | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 | $-0.12 — $-0.12 | -21% YoY | 1 |
| Next Q | $-0.04 | $-0.04 — $-0.04 | 50% YoY | 1 |
| Current FY | $-0.12 ▼ -100.0% | $-0.12 — $-0.12 | 71% YoY | 1 |
| Next FY | $0.40 ▲ +73.9% | $0.40 — $0.40 | 433% YoY | 1 |
Latest Reports
BULLISH
CLUSTER
8/10
Three NEXGEL insiders, including CEO Adam Levy and two directors, made open-market purchases totaling $1.09M at $0.60/sh
May 19, 2026
BEARISH
PRESS-RELEASE
7/10
NEXGEL reported Q4 2025 EPS of -$0.12, a 71.4% miss vs the $0.07 consensus estimate, with revenue of $3.9M in line. The
May 12, 2026
BULLISH
Press
8/10
NEXGEL is acquiring a portfolio of regenerative biomaterial products from Celularity for $15 million upfront and up to $
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| MORGAN STANLEY | $34.8K | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $32.3K | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $21.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Levy Adam | SELL | $1.6K |
| Jun 4, 2026 | Levy Adam | SELL | $1.8K |
| Jun 1, 2026 | Levy Adam | SELL | $1.2K |
| May 29, 2026 | Levy Adam | SELL | $1.8K |
| May 28, 2026 | Levy Adam | SELL | $4.2K |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $130.5K total value (221,687 shares) as of 2026-Q1. Top holders: ROYAL, MORGAN, RENAISSANCE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 32 | $0.00 | 0.0% | — |
| 2 | MORGAN STANLEY | 54,980 | $34.8K | 26.7% | TRIM -35.6% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 50,960 | $32.3K | 24.7% | TRIM -32.8% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 48,920 | $31.0K | 23.7% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 34,040 | $21.5K | 16.5% | — |
| 6 | STATE STREET CORP | 17,259 | $10.9K | 8.4% | — |
| 7 | HRT FINANCIAL LP | 15,496 | $9.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 85,404 | 54,980 | -35.6% | $34.8K | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 68,650 | 123,609 | +80.1% | $301.6K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 121,554 | 87,104 | -28.3% | $212.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2 | 346 | +17200.0% | $844.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 50,102 | 68,650 | +37.0% | $177.1K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 81,631 | 54,831 | -32.8% | $141.5K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 158,331 | 81,631 | -48.4% | $243.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 28,455 | 158,331 | +456.4% | $706.2K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1,600 | 87,804 | +5387.8% | $391.6K | 2024-Q4 |
| VANGUARD GROUP INC | ADD | 28,626 | 49,975 | +74.6% | $128.9K | 2024-Q3 |
3 unique insiders with 12 transactions. Net insider value: $1.1M ($1.1M bought, $12.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Levy Adam R. | Chief Executive Officer | SELL | 3,000 | $0.5470 | $1.6K |
| Jun 4, 2026 | Levy Adam R. | Chief Executive Officer | SELL | 3,000 | $0.5936 | $1.8K |
| Jun 1, 2026 | Levy Adam R. | Chief Executive Officer | SELL | 2,000 | $0.5859 | $1.2K |
| May 29, 2026 | Levy Adam R. | Chief Executive Officer | SELL | 3,000 | $0.6003 | $1.8K |
| May 28, 2026 | Levy Adam R. | Chief Executive Officer | SELL | 7,000 | $0.6058 | $4.2K |
| May 27, 2026 | Levy Adam R. | Chief Executive Officer | SELL | 3,000 | $0.5975 | $1.8K |
| May 14, 2026 | Levy Adam R. | Chief Executive Officer | BUY | 100,000 | $0.6000 | $60.0K |
| May 14, 2026 | Levy Adam R. | Chief Executive Officer | BUY | 50,000 | — | — |
| May 14, 2026 | Henry Scott Robert | Director | BUY | 41,667 | $0.6000 | $25.0K |
| May 14, 2026 | Henry Scott Robert | Director | BUY | 20,834 | — | — |
| May 11, 2026 | Kieser Brian Joseph | Director | BUY | 1,666,667 | $0.6000 | $1.0M |
| May 11, 2026 | Kieser Brian Joseph | Director | BUY | 833,334 | — | — |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 7.5/10.
Historical analyst distribution (last covering-analyst action Mar 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$2.00 mean target (Mar 2026)
$2.00 Low
$2.00 High
| Metric | Value |
|---|---|
| Current Price | $0.5510 |
| Target Low | $2.00 |
| Target Mean | $2.00 |
| Target Median | $2.00 |
| Target High | $2.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.12 | $-0.12 | -21.5% | — | — | $0.0B | 49.6% | 1 |
| Next Q 2026-09-30 |
$-0.04 | $-0.04 | $-0.04 | 50.0% | — | — | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-0.12 | $-0.12 | $-0.12 | 71.3% | -100.0% | 0↑ 1↓ | $0.0B | 110.7% | 1 |
| Next FY 2027-12-31 |
$0.40 | $0.40 | $0.40 | 433.3% | +73.9% | 1↑ 0↓ | $0.0B | 41.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $0.180 | -0.300 |
| 30d ago | $0.000 | -0.120 |
| 60d ago | $0.000 | -0.120 |
| 90d ago | $0.000 | -0.120 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
May 18, 2026
earnings_calendar
NXGL Q1 2026 Earnings Scheduled — 2026-05-18
May 15, 2026
earnings_calendar
NXGL Q1 2026 Earnings Scheduled — 2026-05-15
May 12, 2026
earnings
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
<p align="center"><i>Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day</i></p>
May 11, 2026
earnings_calendar
NXGL Q1 2026 Earnings Scheduled — 2026-05-11
Apr 17, 2026
routine
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
<p align="justify"><strong>LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- </strong>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a
Apr 15, 2026
routine
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
<p align="justify"><strong>LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- </strong>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a
Apr 8, 2026
routine
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
<p align="justify"><strong>LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- </strong>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a
Apr 8, 2026
earnings_calendar
NXGL Q1 2026 Earnings Scheduled — 2026-04-08
Mar 31, 2026
earnings
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
<p align="justify"><strong>LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- </strong>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a
Mar 31, 2026
earnings_calendar
NXGL Q4 2025 Earnings After Market Close — 2026-03-31
Mar 30, 2026
earnings_calendar
NXGL Q4 2025 Earnings After Market Close — 2026-03-30
Mar 12, 2026
m_and_a
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
<p align="center"><i>Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in miles
Mar 10, 2026
m_and_a
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
<p align="center"><i>Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company imm